Vol. 5 No. 6 (2025)
Reimbursement Reviews

Talquetamab (Talvey)

decorative image of the issue cover

Published June 26, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Tarlatamab 1 mg or 10 mg, initial dose of 1 mg on day 1 followed by 10 mg on day 8 and day 15 and q.2.w. thereafter, IV infusion.
  • Indication: For the treatment of adult patients with ES-SCLC with disease progression on or after at least 2 prior lines of therapy including platinum-based chemotherapy